Therapeutic Asset Ratings

3,774 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Jcar017 (Lisocabtagene Maraleucel) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Fred Hutchinson Cancer Center	P2	CCC (52)
Kyv-101 Multiple Sclerosis	Kyverna Therapeutics	P2	CCC (52)
Letetresgene Autoleucel Neoplasm	USWM CT, LLC	P2	CCC (52)
Liocyx-M Hepatocellular Carcinoma	Lion TCR Pte. Ltd.	P2	CCC (52)
Pcar-19B Cells Acute Lymphoblastic Leukemia	Chongqing Precision Biotech Co., Ltd	P2	CCC (52)
Rb-Adsc Alzheimer Disease	Regeneration Biomedical, Inc.	P2	CCC (52)
Tolerogenic Dendritic Cells Multiple Sclerosis	University Hospital, Antwerp	P2	CCC (52)
Young Til Melanoma	National Cancer Institute (NCI)	P2	CCC (52)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Chronic Myeloid Leukemia	David Wald	P1	CCC (52)
cd19-ucart B-Cell Adult Acute Lymphocytic Leukemia	The General Hospital of Western Theater Command	P1	CCC (52)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Plasma Cell Myeloma	David Wald	P1/2	CCC (52)
Anti-Cd19/Cd22 Car-T Cells Follicular Lymphoma	First Affiliated Hospital Xi'an Jiaotong University	P1/2	CCC (52)
Anti-Gprc5D Car-T Cells Plasma Cell Myeloma	XuYan	P1/2	CCC (52)
Ari-0001 Refractory Chronic Lymphocytic Leukemia	GUSTAVO SALGUERO	P1/2	CCC (52)
Bcma-Cart Cells Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (52)
cd19-ucart Childhood Acute Lymphoblastic Leukemia	University Hospital Tuebingen	P1/2	CCC (52)
cd19-ucart CLL	University Hospital Tuebingen	P1/2	CCC (52)
cd22 car-transduced t cells Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Ohio State University Comprehensive Cancer Center	P1/2	CCC (52)
Chimeric Antigen Receptor Modified T Cells Infusion Lymphoproliferative Disorders	UNC Lineberger Comprehensive Cancer Center	P1/2	CCC (52)
hem101 Acute Lymphoblastic Leukemia	National Research Center for Hematology, Russia	P1/2	CCC (52)
Mb-Cart20.1 Non-Hodgkin Lymphoma	Miltenyi Biomedicine GmbH	P1/2	CCC (52)
Mesocella-Ortho Administration Osteoarthritis, Knee	Jagiellonian University	P1/2	CCC (52)
Rapa-501 Autologous T Stem Cells Amyotrophic Lateral Sclerosis	Rapa Therapeutics LLC	P2/3	CCC (52)
Therapeutic Autologous Lymphocytes Leukemia	Memorial Sloan Kettering Cancer Center	P1/2	CCC (52)
Allogeneic Adipose-Derived Mesenchymal Stem Cells Multiple Sclerosis	Hope Biosciences Research Foundation	P2	CCC (51)

Showing 451 to 475 of 3,774 assets

PreviousPage 19 of 151Next